Xiaofei Li

Capital Medical University — China

Medicine · Health Sciences

22h-index2.1kcitations75works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(31), Lung Cancer Research Studies(19), Lung Cancer Diagnosis and Treatment(15), Gastric Cancer Management and Outcomes(5), Colorectal Cancer Treatments and Studies(5)

Publications75 total

2615P Belzutifan plus Lenvatinib for Chinese participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Updated results of cohort 1 of the LITESPARK-010 study
Annals of Oncology·2025
Multifunctional piezoelectric hydrogels under ultrasound stimulation boost chondrogenesis by recruiting autologous stem cells and activating the Ca2+/CaM/CaN signaling pathway
Bioactive Materials·2025· 2 citedOpen Access
Correction to “Ultrasmall Prussian Blue Nanozyme Attenuates Osteoarthritis by Scavenging Reactive Oxygen Species and Regulating Macrophage Phenotype”
Nano Letters·2025· 2 cited
Nodular Regenerative Hyperplasia of the Liver
2025
EE342 The Budget Impact of Introducing an Arterial Blood Gas Syringe With or Without an Automatic Blood Gas Analyzers in Intensive Care Unit in China
Value in Health·2024Open Access
The Evaluation of Urinary HE4, CEA, ProGRP, CYFRA 21-1 and NSE in the Diagnosis of Lung Cancer.
PubMed·2024
Ultrasmall Prussian Blue Nanozyme Attenuates Osteoarthritis by Scavenging Reactive Oxygen Species and Regulating Macrophage Phenotype
Nano Letters·2024· 30 cited
[Prevalence of <i>Enterobius vermicularis</i> infections among children in China from 2016 to 2021: a meta-analysis].
PubMed·2024
74P Five-year survival outcomes of camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic NSCLC: A phase II study
ESMO Open·2024Open Access
84P Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase III CAPSTONE-1 study
Immuno-Oncology Technology·2023· 3 citedOpen Access
1011P A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Annals of Oncology·2023· 2 cited
Successful therapy by WBRT with concurrent intrathecal MTX for isolated leptomeningeal metastasis in ER+ HER2− breast cancer: case report
Research Square (Research Square)·2023Open Access
[CIC-rearranged sarcoma: a clinicopathological analysis of four cases].
PubMed·2023
P-397 The effect of letrozole overlapped with gonadotropin on IVF outcomes in women with DOR or aged over 40 years old
Human Reproduction·2023Open Access
[Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].
PubMed·2023
The feasibility and safety of combining atrial septal defect/patent foramen ovale and left atrial appendage closure: A systematic review and meta-analysis
Frontiers in Cardiovascular Medicine·2023· 5 citedOpen Access
[CIC-rearranged sarcoma with rhabdoid features: a clinicopathological analysis].
PubMed·2022· 1 cited
Hyper-CVAD-Based Stem Cell Microtransplant as Post-Remission Therapy in Acute Lymphoblastic Leukemia
Stem Cells Translational Medicine·2022· 3 citedOpen Access
Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer
Journal of Clinical Oncology·2022· 59 cited
Cutaneous metastases of internal malignancies: a single‐institution experience
Histopathology·2022· 21 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Lin Xu(15), Chun Chen(12), Weimin Mao(10), Shidong Xu(10), Ying Cheng(9), Qun Wang(8), Lin Wu(8), Yi Shen(8), Yi‐Long Wu(8), Wen‐Zhao Zhong(7), Cheng Huang(7), Ke‐Neng Chen(7), Lunxu Liu(7), Hong‐Hong Yan(7), Xue‐Ning Yang(7), Zhidong Liu(6), Buhai Wang(6), Zheng Xiao(6), Cheng-Qiong Wang(6), Jihong Feng(6)